Michael Gwarisa
Zimbabwean scientist Dr. Tariro Makadzange has been named to the TIME100 Health 2026 list by TIME, a recognition that signals the growing prominence of Africa-led clinical trials infrastructure.
The list spotlights the 100 most influential leaders in health from around the world in 2026. Dr Makadzange is the founder and Chief Executive Officer of the Africa Clinical Research Network (ACRN).
In a statement, ACRN said the recognition underscores a broader shift underway, with research in Africa increasingly being led by a new generation of clinical researchers supported by African infrastructure capable of contributing meaningfully to global drug and vaccine development.
“Our focus is not on isolated trials,” said Dr Makadzange. “It is on building durable infrastructure that allows African investigators and institutions to participate in — and shape — global evidence generation.”
While major components of the life sciences value chain, including molecule discovery, immunogen design, animal studies and large-scale manufacturing, require long-term industrial investment, Africa has already benefited from decades of global health investment in epidemiology, translational research and bench science training.
One of the most immediate opportunities for competitive growth lies in clinical development and clinical trials. Clinical trials are a knowledge-driven industry that relies less on extractive resources and more on intellectual capital, regulatory clarity, digital infrastructure and coordinated site networks.
With the right policy frameworks, African countries can compete globally in this space by following models demonstrated by countries such as China and Australia, which deliberately structured regulatory and fiscal environments to attract and scale clinical research activity.
ACRN is building a pan-African platform designed to support that transition. The organization works with clinical trial sites and investigators across multiple countries to reduce trial execution risks through standardized quality frameworks, implement digitized and interoperable clinical trial systems, embed AI-enabled operational and data tools to improve efficiency, strengthen regulatory engagement and harmonization, support policy environments that attract global research investment, and build sustained community trust in science beyond any single study.
Although health systems across the continent face efficiency and infrastructure challenges, these gaps also represent opportunity. Strategic investments in coordinated site networks, regulatory strengthening, digital platforms and workforce development could position Africa as a competitive destination for global clinical research. This would accelerate access to innovation while strengthening local health systems.
The TIME100 Health recognition signals growing international acknowledgment that Africa’s role in global clinical development is evolving. ACRN views this moment as the beginning of a longer journey focused on building a trusted, quality-driven and technology-enabled platform that integrates research, policy, community engagement and scientific leadership across the continent.
